DRUGS & SUPPLEMENTS
How long you have been taking the medicine?
WARNING: ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including Formotil, the active ingredient in Formotil Inhalation Solution. The safety and efficacy of Formotil in patients with asthma have not been established. All LABA, including Formotil, are contraindicated in patients with asthma without use of a long-term asthma control medication .
WARNING: ASTHMA-RELATED DEATH
See full prescribing information for complete boxed warning.
Formotil Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for:
Important limitations of use:
Formotil (formoterol fumarate) Inhalation Solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Formotil Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease .
Formotil Inhalation Solution is not indicated to treat asthma. The safety and effectiveness of Formotil Inhalation Solution in asthma have not been established.
The recommended dose of Formotil (formoterol fumarate) Inhalation Solution is one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose greater than 40 mcg is not recommended.
Formotil Inhalation Solution should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor. The safety and efficacy of Formotil Inhalation Solution have been established in clinical trials when administered using the PARI-LC Plus® nebulizer (with a facemask or mouthpiece) and the PRONEB® Ultra compressor. The safety and efficacy of Formotil Inhalation Solution delivered from non-compressor based nebulizer systems have not been established.
Formotil Inhalation Solution should always be stored in the foil pouch, and only removed IMMEDIATELY BEFORE USE. Contents of any partially used container should be discarded.
If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be re-evaluated and additional therapeutic options should be considered.
The drug compatibility (physical and chemical), efficacy, and safety of Formotil Inhalation Solution when mixed with other drugs in a nebulizer have not been established.
For oral inhalation only.
Formotil (formoterol fumarate) Inhalation Solution is supplied as a sterile solution for nebulization in low-density polyethylene unit-dose vials. Each vial contains Formotil fumarate dihydrate, USP equivalent to 20 mcg/2 mL of Formotil fumarate.
Inhalation Solution (unit dose vial for nebulization); 20 mcg/2 mL solution (3)
All LABA, including Formotil, are contraindicated in patients with asthma without use of a long-term asthma control medication. .
Data from a large placebo-controlled study in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death. Data are not available to determine whether the rate of death in patients with COPD is increased by long-acting beta2-adrenergic agonists.
A 28-week, placebo-controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). The increased risk of asthma-related death is considered a class effect of the long-acting beta2-adrenergic agonists, including Formotil Inhalation Solution. No study adequate to determine whether the rate of asthma related death is increased in patients treated with Formotil Inhalation Solution has been conducted. The safety and efficacy of Formotil in patients with asthma have not been established. All LABA, including Formotil, are contraindicated in patients with asthma without use of a long-term asthma control medication. .
Clinical studies with Formotil fumarate administered as a dry powder inhaler suggested a higher incidence of serious asthma exacerbations in patients who received Formotil than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.
Formotil Inhalation Solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. Formotil Inhalation Solution has not been studied in patients with acutely deteriorating COPD. The use of Formotil Inhalation Solution in this setting is inappropriate.
Formotil Inhalation Solution should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Formotil Inhalation Solution has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.
When beginning Formotil Inhalation Solution, patients who have been taking inhaled, short-acting beta2-agonists on a regular basis should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing Formotil Inhalation Solution, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If Formotil Inhalation Solution no longer controls the symptoms of bronchoconstriction, or the patient’s inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of Formotil Inhalation Solution beyond the recommended 20 mcg twice daily dose is not appropriate in this situation.
As with other inhaled beta2-adrenergic drugs, Formotil Inhalation Solution should not be used more often, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
As with other inhaled beta2-agonists, Formotil Inhalation Solution can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, Formotil Inhalation Solution should be discontinued immediately and alternative therapy instituted.
Formotil Inhalation Solution, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic and/or diastolic blood pressure, and/or symptoms. If such effects occur, Formotil Inhalation Solution may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Formotil Inhalation Solution, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Formotil Inhalation Solution, like other sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to sympathomimetic amines. Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.
Beta-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects . The decrease in serum potassium is usually transient, not requiring supplementation. Beta-agonist medications may produce transient hyperglycemia in some patients.
Clinically significant changes in serum potassium and blood glucose were infrequent during clinical studies with long-term administration of Formotil Inhalation Solution at the recommended dose.
Immediate hypersensitivity reactions may occur after administration of Formotil Inhalation Solution, as demonstrated by cases of anaphylactic reactions, urticaria, angioedema, rash, and bronchospasm.
Long acting beta2-adrenergic agonists such as Formotil increase the risk of asthma-related death .
Most common adverse reactions (>2% and more common than placebo) are diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia (6.2)
To report SUSPECTED ADVERSE REACTIONS, contact Mylan Specialty L.P. at 1-800-429-7751 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Adverse reactions to Formotil Inhalation Solution are expected to be similar in nature to other beta2-adrenergic receptor agonists including: angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, muscle cramps, palpitations, nausea, dizziness, fatigue, malaise, insomnia, hypokalemia, hyperglycemia, and metabolic acidosis.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Formotil Inhalation Solution 20 mcg twice daily by oral inhalation in 586 patients, including 232 exposed for 6 months and 155 exposed for at least 1 year. Formotil Inhalation Solution was studied in a 12-week, placebo- and active-controlled trial and a 52-week, active-controlled trial (463 subjects treated with Formotil Inhalation Solution). Patients were mostly Caucasians (88%) between 40-90 years old (mean, 64 years old) and had COPD, with a mean FEV1 of 1.33 L. Patients with significant concurrent cardiac and other medical diseases were excluded from the trials.
Table 1 shows adverse reactions from the 12-week, double-blind, placebo-controlled trial where the frequency was greater than or equal to 2% in the Formotil Inhalation Solution group and where the rate in the Formotil Inhalation Solution group exceeded the rate in the placebo group. In this trial, the frequency of patients experiencing cardiovascular adverse events was 4.1% for Formotil Inhalation Solution and 4.4% for placebo. There were no frequently occurring specific cardiovascular adverse events for Formotil Inhalation Solution (frequency greater than or equal to 1% and greater than placebo). The rate of COPD exacerbations was 4.1% for Formotil Inhalation Solution and 7.9% for placebo.
Number of patients with adverse reactions in the 12-week multiple-dose controlled clinical trial
Patients treated with Formotil Inhalation Solution 20 mcg twice daily in the 52-week open-label trial did not experience an increase in specific clinically significant adverse events above the number expected based on the medical condition and age of the patients.
The following adverse reactions have been reported during post-approval use of Formotil Inhalation Solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Anaphylactic reactions, urticaria, angioedema (presenting as face, lip, tongue, eye, pharyngeal, or mouth edema), rash, and bronchospasm
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of Formotil may be potentiated .
Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists .
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
Formotil, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.
Beta-adrenergic receptor antagonists (beta-blockers) and Formotil may inhibit the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
Formotil fumarate administered throughout organogenesis did not cause malformations in rats or rabbits following oral administration. However, Formotil fumarate was found to be teratogenic in rats and rabbits in other testing laboratories. When given to rats throughout organogenesis, oral doses of 0.2 mg/kg and above delayed ossification of the fetus, and doses of 6 mg/kg (approximately 1200 times the maximum recommended daily inhalation dose in humans on a mg/m2 basis) and above decreased fetal weight. Formotil fumarate has been shown to cause stillbirth and neonatal mortality at oral doses of 6 mg/kg and above in rats receiving the drug during the late stage of pregnancy. These effects, however, were not produced at a dose of 0.2 mg/kg. Because there are no adequate and well-controlled studies in pregnant women, Formotil Inhalation Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Women should be advised to contact their physician if they become pregnant while taking Formotil Inhalation Solution.
There are no adequate and well-controlled human studies that have investigated the effects of Formotil Inhalation Solution during labor and delivery.
Because beta-agonists may potentially interfere with uterine contractility, Formotil Inhalation Solution should be used during labor only if the potential benefit justifies the potential risk.
In reproductive studies in rats, Formotil was excreted in the milk. It is not known whether Formotil is excreted in human milk, but because many drugs are excreted in human milk, caution should be exercised if Formotil Inhalation Solution is administered to nursing women. There are no well-controlled human studies of the use of Formotil Inhalation Solution in nursing mothers.
Women should be advised to contact their physician if they are nursing while taking Formotil Inhalation Solution.
Formotil Inhalation Solution is not indicated for use in children. The safety and effectiveness of Formotil Inhalation Solution in pediatric patients have not been established. The pharmacokinetics of Formotil fumarate has not been studied in pediatric patients.
Of the 586 subjects who received Formotil Inhalation Solution in clinical studies, 284 were 65 years and over, while 89 were 75 years and over. Of the 123 subjects who received Formotil Inhalation Solution in the 12-week safety and efficacy trial, 48 (39%) were 65 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.
The pharmacokinetics of Formotil Inhalation Solution has not been studied in elderly subjects.
The expected signs and symptoms with overdosage of Formotil Inhalation Solution are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms listed under ADVERSE REACTIONS. Signs and symptoms may include angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, and metabolic acidosis. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of Formotil Inhalation Solution.
Treatment of overdosage consists of discontinuation of Formotil Inhalation Solution together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Formotil Inhalation Solution. Cardiac monitoring is recommended in cases of overdosage.
The minimum lethal inhalation dose of Formotil fumarate in rats is 156 mg/kg (approximately 32,000 times the maximum recommended daily inhalation dose in humans on a mg/m2 basis). The median lethal oral doses in Chinese hamsters, rats, and mice provide even higher multiples of the maximum recommended daily inhalation dose in humans.
For additional information about overdose treatment, call a poison control center (1-800-222-1222).
Formotil (formoterol fumarate) Inhalation Solution is supplied as 2 mL of Formotil fumarate inhalation solution packaged in a 2.5 mL single-use low-density polyethylene vial and overwrapped in a foil pouch. Each vial contains 2 mL of a clear, colorless solution composed of Formotil fumarate dihydrate, USP equivalent to 20 mcg of Formotil fumarate in an isotonic, sterile aqueous solution containing sodium chloride, pH adjusted to 5.0 with citric acid and sodium citrate.
The active component of Formotil Inhalation Solution is Formotil fumarate dihydrate, USP, a racemate. Formotil fumarate dihydrate is a beta2-adrenergic bronchodilator. Its chemical name is (±)-2-hydroxy-5-[(1RS)-1-hydroxy-2-[[(1RS)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]formanilide fumarate dihydrate; its structural formula is:
Figure 2 Mean* FEV1 at Endpoint after 12 Weeks of Treatment
Patients treated with Formotil Inhalation Solution used less rescue albuterol during the trial compared to patients treated with placebo.
Examination of age (≥ 65 or younger) and gender subgroups did not identify differences in response to Formotil Inhalation Solution. There were too few non-Caucasian subjects to assess differences in populations defined by race adequately.
In the 12 week study, 78% of subjects achieved a 15% increase from baseline FEV1 following the first dose of Formotil Inhalation Solution 20 mcg. In these subjects, the median time to onset of bronchodilation, defined as 15% increase in FEV1, was 11.7 minutes. When defined as an increase in FEV1 of 12% and 200 mL, the time to onset of bronchodilation was 13.1 minutes after dosing. The median time to peak bronchodilator effect was 2 hours after dosing.
Formotil (formoterol fumarate) Inhalation Solution is supplied as a 2 mL sterile solution for nebulization in 2.5 mL low-density polyethylene unit dose vials. Each vial is overwrapped in a foil pouch and supplied in cartons as listed below.
Carton of 30 individually wrapped unit dose vials, NDC 49502-605-30
Carton of 60 individually wrapped unit dose vials, NDC 49502-605-61
Storage and Handling:
Prior to dispensing to the patient: Store in a refrigerator, 2°C to 8°C (36°F to 46°F)
After dispensing to the patient: Store at 2°C to 25°C (36°F to 77°F) for up to 3 months. Protect pouch from heat.
Patients should be informed that long acting beta agonist, such as Formotil, increase the risk of asthma-related death. All LABA, including Formotil, should not be used in patients with asthma without use of a long-term asthma control medication.
Acute Exacerbations or Deteriorations
Formotil Inhalation Solution is not indicated for relief of acute symptoms, and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist (the healthcare provider should provide the patient with such medication and instruct the patient in how it should be used). Patients should be instructed to seek medical attention if their symptoms worsen despite recommended doses of Formotil Inhalation Solution, if Formotil Inhalation Solution treatment becomes less effective, or if they need more inhalations of a short-acting beta2-agonist than usual.
Patients should not stop using Formotil Inhalation Solution unless told to do so by a healthcare provider because symptoms may get worse. Patients should not inhale more than the prescribed number of vials at any one time. The daily dosage of Formotil Inhalation Solution should not exceed one vial twice daily (40 mcg total daily dose). Excessive use of sympathomimetics may cause significant cardiovascular effects, and may be fatal.
Patients who have been taking inhaled, short-acting beta2-agonists (e.g., albuterol) on a regular basis should be instructed to discontinue the regular use of these products and use them only for symptomatic relief of acute symptoms. Formotil Inhalation Solution should not be used in conjunction with other inhaled medications containing long-acting beta2-agonists. Patients should be warned not to stop or change the dose of other concomitant COPD therapy without medical advice, even if symptoms improve after initiating treatment with Formotil Inhalation Solution.
Common Adverse Reactions with Beta2-agonists
Patients should be informed that treatment with beta2-agonists may lead to adverse reactions that include palpitations, chest pain, rapid heart rate, increased or decreased blood pressure, headache, tremor, nervousness, dry mouth, muscle cramps, nausea, dizziness, fatigue, malaise, low blood potassium, high blood sugar, high blood acid, or trouble sleeping .
Instructions for Administration
It is important that patients understand how to use Formotil Inhalation Solution with a nebulizer appropriately . Patients should be instructed not to mix other medications with Formotil Inhalation Solution or ingest Formotil Inhalation Solution. Patients should throw the plastic dispensing container away immediately after use. Due to their small size, the container and top pose a danger of choking to young children.
FDA-Approved Medication Guide
See the accompanying Medication Guide.
Mylan Specialty L.P.
Morgantown, WV 26505
The Ritedose Corporation
Columbia, SC 29203
U.S. Pat. No. 6,667,344
U.S. Pat. No. 6,814,953
(formoterol fumarate) Inhalation Solution
Formotil Inhalation Solution is only for use with a nebulizer.
Read the Medication Guide that comes with Formotil Inhalation Solution before you start using it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment.
What is the most important information I should know about Formotil Inhalation Solution?
Formotil Inhalation Solution can cause serious side effects including:
What is Formotil Inhalation Solution?
Formotil Inhalation Solution is used long term, 2 times a day (morning and evening), in controlling symptoms of chronic obstructive pulmonary disease (COPD) in adults with COPD.
Formotil Inhalation Solution is only for use with a nebulizer. LABA medicines such as Formotil Inhalation Solution help the muscles around the airways in your lungs stay relaxed to prevent symptoms, such as wheezing, cough, chest tightness, and shortness of breath.
Formotil Inhalation Solution is not for use to treat sudden symptoms of COPD.
Formotil Inhalation Solution should not be used in children. It is not known if Formotil Inhalation Solution is safe and effective in children.
It is not known if Formotil Inhalation Solution is safe and effective in people with asthma.
Who should not use Formotil Inhalation Solution?
Do not use Formotil Inhalation Solution if you have asthma without using a long-term asthma control medicine.
What should I tell my healthcare provider before using Formotil Inhalation Solution?
Tell your healthcare provider about all of your health conditions, including if you:
Tell your healthcare provider about all the medicines you take including prescription and non-prescription medicines, vitamins and herbal supplements. Formotil Inhalation Solution and certain other medicines may interact with each other. This may cause serious side effects.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine.
How should I use Formotil Inhalation Solution?
Read the step-by-step instructions for using Formotil Inhalation Solution at the end of this Medication Guide.
Call your healthcare provider or get emergency medical care right away if:
What are the possible side effects of Formotil Inhalation Solution?
Formotil Inhalation Solution can cause serious side effects, including:
Common side effects of Formotil Inhalation Solution include:
Tell your healthcare provider if you get any side effect that bothers you or that does not go away.
These are not all the side effects with Formotil Inhalation Solution. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Formotil Inhalation Solution?
General Information about Formotil Inhalation Solution
Medicines are sometimes prescribed for purposes that are not mentioned in a Medication Guide. Do not use Formotil Inhalation Solution for a condition for which it was not prescribed. Do not give Formotil Inhalation Solution to other people, even if they have the same condition. It may harm them.
This Medication Guide summarizes the most important information about Formotil Inhalation Solution. If you would like more information, talk with your health care provider. You can ask your health care provider or pharmacist for information about Formotil Inhalation Solution that was written for healthcare professionals.
Instructions for Using Formotil (formoterol fumarate) Inhalation Solution
Formotil Inhalation Solution is used only in a standard jet nebulizer machine connected to an air compressor. Make sure you know how to use your nebulizer machine before you use it to breathe in Formotil Inhalation Solution or other medicines.
Do not mix Formotil Inhalation Solution with other medicines in your nebulizer machine.
Formotil Inhalation Solution comes sealed in a foil pouch. Do not open a sealed pouch until you are ready to use a dose of Formotil Inhalation Solution.
Mylan Specialty L.P.
Morgantown, WV 26505
The Ritedose Corporation
Columbia, SC 29203
Revised MARCH 2013
This Medication Guide has been approved by the U.S. Food and Drug Administration
Figure 1 Figure 2 Figures 3 and 4
PRINCIPAL DISPLAY PANEL - 20 mcg/2 mL vial
(formoterol fumarate) INHALATION SOLUTION
20 mcg/2 mL vial
Medication Guide For Patients Enclosed
Sterile Unit Dose Vials - Individually Wrapped - For Oral Inhalation Only
CARTON CONTAINS: 60 individually wrapped 2 mL vials
EACH 2 mL VIAL CONTAINS: ACTIVE: Formotil fumarate, USP.
INACTIVES: Citric acid, sodium citrate, sodium chloride, and water.
PRIOR TO DISPENSING TO THE PATIENT: Store refrigerated, 2°C to 8°C (36°F to 46°F).
AFTER DISPENSING TO THE PATIENT: Store at 2°C to 25°C (36°F to 77°F) for up to 3 months.
Protect pouch from heat. VIAL SHOULD ALWAYS BE STORED IN THE FOIL POUCH, AND ONLY REMOVED IMMEDIATELY BEFORE USE.
Keep out of reach of children.
FOR THE HEALTHCARE PROVIDER: When Formotil® Inhalation Solution is dispensed to the patient, write an expiration date in the "Use by" box on the carton or dispensing container. The date should not exceed either 3 months from date dispensed or the expiration date on the product, whichever comes first. After dispensing to the patient, store at 2°C to 25°C (36°F to 77°F) for up to 3 months.
FOR THE PATIENT: Use Formotil® Inhalation Solution prior to the "Use by" date.
U.S. Pat. Nos. 6,667,344 and 6,814,953
Mylan Specialty L.P., Morgantown, WV 26505
Mylan Specialty L.P.
Morgantown, WV 26505
The Ritedose Corporation
Columbia, SC 29203
Formotil Inhalation Solution 20 mcg/2 mL Carton
Depending on the reaction of the Formotil after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Formotil not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Formotil addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology